Sinovac Biotech (FRA:SVQ) ROCE %: -1.87% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:SVQ Sinovac Biotech Ltd FRA:SVQ
12 GF Score
Price €5.58
! 9 Warning Signs
View Full Analysis

What is Sinovac Biotech ROCE %?

Sinovac Biotech FRA:SVQ 12 ROCE % is -1.87% as of Jun. 2026. GuruFocus rates FRA:SVQ with a GF Score™ of 12/100. The stock has 9 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sinovac Biotech's annualized ROCE % for the quarter that ended in Jun. 2026 was -1.87%.

Sinovac Biotech  (FRA:SVQ) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Sinovac Biotech ROCE % Related Terms

Sinovac Biotech ROCE % Historical Data

* Premium members only.

The historical data trend for Sinovac Biotech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinovac Biotech ROCE % Chart

Sinovac Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 227.09 0.20 -0.61 0.42 -2.63

Sinovac Biotech Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.65 -1.93 -4.56 -1.87
FRA:SVQ
12GF Score
Sinovac Biotech Ltd FRA:SVQ
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sinovac Biotech ROCE % Calculation

Sinovac Biotech's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-215.45/( ( (11782.103 - 1386.563) + (7294.633 - 1315.472) )/ 2 )
=-215.45/( (10395.54+5979.161)/ 2 )
=-215.45/8187.3505
=-2.63 %

Sinovac Biotech's ROCE % of for the quarter that ended in Jun. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2026 )  (Q: Dec. 2025 )(Q: Jun. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2026 )  (Q: Dec. 2025 )(Q: Jun. 2026 )
=-112.956/( ( (7294.633 - 1315.472) + (7064.468 - 947.124) )/ 2 )
=-112.956/( ( 5979.161 + 6117.344 )/ 2 )
=-112.956/6048.2525
=-1.87 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -1.87% mean?
Sinovac Biotech (FRA:SVQ) has a ROCE % of -1.87% as of Jun. 2026.
Is Sinovac Biotech's ROCE % too high?
Sinovac Biotech's current ROCE % is -1.87%. Overall, Sinovac Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Sinovac Biotech's ROCE % compare to INBX and HLVX?
Sinovac Biotech's ROCE % of -1.87% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Sinovac Biotech's current ROCE % is -1.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinovac Biotech stock overvalued right now?
Sinovac Biotech (FRA:SVQ) has a current ROCE % of -1.87%. The current ROCE % is -1.87%. Sinovac Biotech's overall GF Score™ is 12/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Sinovac Biotech (FRA:SVQ), the current ROCE % is -1.87% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sinovac Biotech Business Description

Address No.39, Shangdi Xi Road, Haidan District, Beijing, CHN, 100085
Sinovac Biotech Ltd is a fully integrated China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of vaccines for the prevention of human infectious diseases, including certain diseases with unmet medical needs. It has developed a comprehensive vaccine portfolio covering hepatitis A, hepatitis B, hand, foot and mouth disease ("HFMD") caused by enterovirus 71 ("EV71"), seasonal and pandemic influenza, COVID-19, pneumococcal disease, poliomyelitis, mumps, varicella, rabies and tetanus. The Company operates exclusively in the research, development, manufacture, and commercialization of vaccines sector. The Company's business is considered as operating in one segment. It has presence in Chinese Mainland, and Outside Chinese Mainland.
12GF Score

Get the complete analysis for FRA:SVQ

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.58
Price